Susan N. Payne

599 total citations
7 papers, 226 citations indexed

About

Susan N. Payne is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Susan N. Payne has authored 7 papers receiving a total of 226 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Molecular Biology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Susan N. Payne's work include Colorectal Cancer Treatments and Studies (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Genetic factors in colorectal cancer (2 papers). Susan N. Payne is often cited by papers focused on Colorectal Cancer Treatments and Studies (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Genetic factors in colorectal cancer (2 papers). Susan N. Payne collaborates with scholars based in United States. Susan N. Payne's co-authors include Dustin A. Deming, Kristina A. Matkowskyj, Linda Clipson, Cheri A. Pasch, Molly E. Maher, Alexander E. Yueh, Alyssa A. Leystra, Fotis Asimakopoulos, Philip B. Emmerich and Athanasios Papadas and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Cancer Research.

In The Last Decade

Susan N. Payne

7 papers receiving 224 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susan N. Payne United States 5 135 92 70 41 38 7 226
Fanglei You United States 6 197 1.5× 114 1.2× 88 1.3× 26 0.6× 19 0.5× 9 302
Nicolas Barengo United States 8 97 0.7× 209 2.3× 81 1.2× 52 1.3× 16 0.4× 8 312
Rajeswara Rao Arasada United States 8 159 1.2× 200 2.2× 73 1.0× 38 0.9× 26 0.7× 11 328
Hanna Nyström Sweden 10 154 1.1× 108 1.2× 103 1.5× 20 0.5× 14 0.4× 18 275
Mireia Berdiel‐Acer Spain 9 207 1.5× 151 1.6× 102 1.5× 53 1.3× 35 0.9× 13 313
Jung Hwa Moon South Korea 8 182 1.3× 267 2.9× 117 1.7× 35 0.9× 21 0.6× 10 372
Kathleen Watt Canada 9 108 0.8× 166 1.8× 88 1.3× 37 0.9× 14 0.4× 16 267
Carmine Dell’Aglio Italy 8 93 0.7× 116 1.3× 55 0.8× 35 0.9× 28 0.7× 8 246
Natsumi Kawasaki Japan 9 98 0.7× 231 2.5× 99 1.4× 39 1.0× 39 1.0× 16 336
Renya Zhang China 11 92 0.7× 162 1.8× 69 1.0× 25 0.6× 15 0.4× 21 290

Countries citing papers authored by Susan N. Payne

Since Specialization
Citations

This map shows the geographic impact of Susan N. Payne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan N. Payne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan N. Payne more than expected).

Fields of papers citing papers by Susan N. Payne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan N. Payne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan N. Payne. The network helps show where Susan N. Payne may publish in the future.

Co-authorship network of co-authors of Susan N. Payne

This figure shows the co-authorship network connecting the top 25 collaborators of Susan N. Payne. A scholar is included among the top collaborators of Susan N. Payne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan N. Payne. Susan N. Payne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
DeStefanis, Rebecca A., et al.. (2022). Abstract 1128: MTORC1/2 and HDAC1/2 inhibition promote tumor response through inhibition of MYC. Cancer Research. 82(12_Supplement). 1128–1128. 1 indexed citations
2.
Emmerich, Philip B., Rosabella T. Pitera, Susan N. Payne, et al.. (2019). Abstract 1904: Versican production is driven by both epithelial and stromal cells in pancreatic cancer. Cancer Research. 79(13_Supplement). 1904–1904. 2 indexed citations
3.
Payne, Susan N., Cheri A. Pasch, Linda Clipson, et al.. (2017). Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations. Molecular Cancer Research. 15(3). 317–327. 46 indexed citations
4.
Hope, Chelsea, Philip B. Emmerich, Athanasios Papadas, et al.. (2017). Versican-Derived Matrikines Regulate Batf3–Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer. The Journal of Immunology. 199(5). 1933–1941. 89 indexed citations
5.
Yueh, Alexander E., Susan N. Payne, Alyssa A. Leystra, et al.. (2016). Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K. PLoS ONE. 11(2). e0148730–e0148730. 16 indexed citations
6.
Leystra, Alyssa A., Terrah J. Paul Olson, Molly E. Maher, et al.. (2015). Colon Tumors with the Simultaneous Induction of Driver Mutations in APC , KRAS , and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence. Cancer Prevention Research. 8(10). 952–961. 20 indexed citations
7.
Payne, Susan N., Molly E. Maher, Nguyen H. Tran, et al.. (2015). PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. Oncogenesis. 4(10). e169–e169. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026